Trial design.
BLIND
All participants underwent randomisation and were allocated to either the placebo or testosterone arm.Block randomisation was used to allocate treatment kits 1:1 to either testosterone or placebo at the central pharmacy. Randomised treatment kits were then allocated to participants in consecutive order at their Baseline visit (i.e. First participant enrolled received Treatment Kit no.1). Block size was determined by the central pharmacy. The random allocation sequence was generated by the Central Pharmacy (Lawley Pharmaceuticals). Participants were enrolled by the study PI and research nurses. Treatment kits (and therefore intervention) was assigned by allocation of the next available sequentially numbered Treatment Kit at site. Screening occurred between 10The exercise training program was prescribed by an accredited exercise physiologist and accredited physiotherapist and comprised of light/moderate resistance training, balance training and moderate aerobic exercise component, as detailed in the protocol [The pilot study was conducted as a double blind study. Participants, care providers and study team members were blind to intervention until unblinding of the allocations following database lock. An unblinded safety monitor provided review of safety bloods.